BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Pfizer Inc. (PFE) Settles Patent Litigation With Mylan Inc. (MYL) Covering Detrol LA®


9/7/2012 8:11:34 AM

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. announced that it has settled its litigation against Mylan Inc. and Mylan Pharmaceuticals Inc. relating to Pfizer’s patents covering Detrol LA® (tolterodine tartrate) extended-release capsules.

As a result of this settlement, and past settlements related to these patents, Pfizer expects generic competition for Detrol LA® to commence in the United States no earlier than January 1, 2014, except in certain limited circumstances, and no later than March 1, 2014.

The terms of the settlement agreement are otherwise confidential.

A generic version of Detrol LA® has not been approved to date.

The company indicated that this settlement does not result in any change in its 2012 financial guidance previously updated on August 13, 2012.

DISCLOSURE NOTICE: The information contained in this release is as of September 7, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as a result of new information or future events or developments.

This release contains forward-looking information relating to the anticipated commencement of generic competition for Detrol LA in the U.S. and relating to the Company’s previously provided financial guidance for 2012. Such information involves substantial risks and uncertainties including, among other things, the uncertainties and variables inherent in business operating and financial performance, including, among other things, competitive developments and general economic, political, business, industry, regulatory and market conditions and the other risks and uncertainties set forth in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K.

Contact:

Pfizer Inc.

Media:

Chris Loder, 212-733-7897

or

Investors:

Suzanne Harnett, 212-733-8009


Read at BioSpace.com
Read at Reuters
Read at RTT News


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->